Peptide education
Abaloparatide
Tymlos
Abaloparatide is a prescription medicine that helps build bone. The U.S. product Tymlos is used for certain people with osteoporosis at high risk of fracture. It is a synthetic analog of parathyroid hormone-related protein, not a mineral supplement or a substitute for a complete osteoporosis care plan.
Tymlos is a daily prescription injection with fracture evidence in postmenopausal osteoporosis. The label also covers increasing bone density in men with osteoporosis at high fracture risk, with product-specific safety and treatment-duration limits.
Overview
Quick answer
The U.S. label says Tymlos reduces vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. A European analysis excluding two trial sites found that the nonvertebral result was not statistically significant. In men, the indication is to increase bone density; the male trial did not establish a reduction in fractures.
Who is Tymlos prescribed for?
The U.S. label covers postmenopausal women with osteoporosis at high fracture risk and increasing bone density in men with osteoporosis at high fracture risk. It also includes patients who have failed or cannot tolerate other available osteoporosis medicines.
What does the label say about dose and duration?
The label specifies 80 mcg injected under the skin once daily. It does not recommend using Tymlos for more than two years during a patient's lifetime. A prescriber decides whether the medicine is appropriate for the individual.
What did the main fracture trial find?
In the ACTIVE study of postmenopausal women, new vertebral fractures were found in 0.58% of evaluable participants assigned abaloparatide and 4.22% assigned placebo over 18 months. These are group results, not a prediction of an individual's outcome.
Is it the same as teriparatide?
No. Both medicines activate the PTH1 receptor, but they are different molecules with different product labels. ACTIVE included a teriparatide arm, but its primary vertebral-fracture comparison was abaloparatide versus placebo, not a powered head-to-head test of the two medicines.
Evidence
Evidence snapshot
The approved product is for specified high-risk osteoporosis populations, including postmenopausal women and men needing an increase in bone density.
The primary vertebral-fracture result was 0.58% with abaloparatide versus 4.22% with placebo among women with evaluable radiographs.
A 12-month placebo-controlled trial in men found greater lumbar spine bone mineral density gains with abaloparatide. It does not establish fracture reduction in that population.
The label includes precautions for high calcium, urinary calcium and kidney stones, dizziness on standing, hypersensitivity, and people at increased baseline risk of osteosarcoma.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Abaloparatide reduces fractures in postmenopausal osteoporosis. | ACTIVE compared 80 mcg daily with placebo over 18 months. Vertebral fractures were identified in 0.58% versus 4.22% of evaluable women. The original analysis also reported fewer nonvertebral fractures with abaloparatide. | The medicine activates PTH1 receptors and stimulates bone formation. | The U.S. label describes reductions in both fracture types. A European assessment excluded two trial sites because of serious conduct concerns. In that analysis, the vertebral result remained significant, while the nonvertebral difference did not. Estimated nonvertebral event rates at 19 months were 2.7% versus 3.6%, with a hazard ratio of 0.74 and a 95% confidence interval of 0.38 to 1.43. |
| Abaloparatide has the same fracture proof in men. | The male ATOM trial randomized 228 men and measured lumbar spine bone mineral density as its primary outcome. Bone density increased more with abaloparatide than placebo over 12 months. | The male indication is to increase bone density. A density result should not be described as a demonstrated fracture reduction in this trial. | |
| ACTIVE proves abaloparatide is better than teriparatide at preventing vertebral fractures. | ACTIVE included open-label teriparatide, while abaloparatide and placebo were blinded. Its primary comparison was abaloparatide versus placebo; the investigators did not design the trial to establish a difference between the active medicines for the primary vertebral-fracture endpoint. | Do not infer superiority from separate comparisons with placebo or from the small number of fractures in the two active groups. | |
| A bone-building course can be followed by another osteoporosis medicine. | In ACTIVExtend, eligible women from the abaloparatide and placebo groups of ACTIVE received open-label alendronate after the initial study. Bone-density gains continued during the extension. | This is one studied sequence. A follow-on choice depends on the patient's history, risks, and clinician's assessment. |
Bottom line
Main takeaway
Tymlos is a medicine for building bone in specific high-risk settings. A person's prior fractures, bone-density results, other conditions, and treatment history all matter when discussing options with a clinician.
Compare the population and outcome, not just the drug names. A fracture trial in postmenopausal women and a bone-density trial in men answer different questions. Tymlos and Forteo also have different label details.
Read the Tymlos label alongside ACTIVE, ATOM, and ACTIVExtend. Check the fracture analysis population, open-label comparator, and extension design before comparing outcomes.
Identity
What it is
Abaloparatide is a 34-amino-acid analog of parathyroid hormone-related protein. Tymlos is supplied as a single-patient-use injection pen.
Osteoporosis treatment addresses fracture risk as well as bone density. The label identifies high-risk populations and patients for whom other available osteoporosis treatment has failed or was not tolerated.
Use context
Routes, doses, and cycle patterns
Tymlos is injected under the skin once daily. The prescribed course and follow-on treatment depend on a patient's fracture risk and medical history.
Human studies and product labels
Tymlos U.S. label
- Purpose
- Treatment of labeled high-risk osteoporosis populations
- Context
- Approved prescription product
- Route
- Subcutaneous injection in the abdomen around the navel
- Amount
- 80 mcg
- Frequency
- Once daily
- Duration
- More than two years of lifetime use is not recommended
The label advises injection-site rotation and a setting where the patient can sit or lie down for the first several doses if dizziness occurs. Calcium and vitamin D supplementation is addressed when dietary intake is inadequate.
ACTIVE study
- Purpose
- Fracture outcomes in postmenopausal osteoporosis
- Context
- Study-reported regimen, not a recommendation
- Route
- Subcutaneous
- Amount
- 80 mcg
- Frequency
- Once daily
- Duration
- 18 months
The trial compared blinded abaloparatide with placebo and included open-label teriparatide. The primary endpoint was new vertebral fracture for abaloparatide versus placebo.
ATOM study
- Purpose
- Bone-density outcomes in men with osteoporosis
- Context
- Study-reported regimen, not a recommendation
- Route
- Subcutaneous
- Amount
- 80 mcg
- Frequency
- Once daily
- Duration
- 12 months
The primary outcome was lumbar spine bone mineral density, not fractures.
What varies
- Tymlos is refrigerated before first use. After first use, its label specifies room-temperature storage at 20 to 25 C for up to 30 days, then disposal of the pen even if medicine remains. Do not freeze or expose it to heat.
- Previous bone cancer, skeletal radiation, Paget's disease, high calcium, kidney stones, and serious drug allergies are important topics for a prescriber before treatment.
- The ACTIVExtend sequence studied alendronate after abaloparatide. A plan for what happens after a bone-building course is a separate clinical decision.
Research
Research evidence
The strongest fracture results come from postmenopausal women in ACTIVE. ATOM assessed bone density in men, and ACTIVExtend followed eligible ACTIVE participants into a shared alendronate treatment period.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| ACTIVE | 2,463 randomized postmenopausal women with osteoporosis | Randomized, abaloparatide and placebo blinded, teriparatide open-label | Daily subcutaneous abaloparatide 80 mcg for 18 months | New vertebral fracture in 0.58% with abaloparatide vs 4.22% with placebo among evaluable women | Manufacturer-funded trial, not powered for the primary vertebral-fracture comparison between active drugs. A European analysis excluded two sites because of conduct concerns; the nonvertebral difference was no longer statistically significant. | Controlled fracture endpoint in a defined population |
| ATOM | 228 men with osteoporosis | Randomized, double-blind, placebo-controlled | Daily subcutaneous abaloparatide 80 mcg for 12 months | Greater lumbar spine bone-density gain than placebo | Bone density was the primary endpoint, not fracture reduction | Controlled density endpoint in men |
| ACTIVExtend | Eligible women from the abaloparatide and placebo arms of ACTIVE | Extension with open-label alendronate in both groups | Initial 18-month study followed by up to 24 months of alendronate | Bone-density gains continued during the extension | Selected participants entered the extension and both groups received alendronate | Sequential treatment evidence, not an untreated follow-up comparison |
Cautions
Safety and unknowns
- Dizziness, nausea, palpitations, and injection-site reactions are among the adverse effects described in the label. Early doses may cause a drop in blood pressure on standing.
- Tymlos can raise blood or urine calcium. The label discourages use with pre-existing high blood calcium or an underlying hypercalcemic disorder, and discusses urine-calcium assessment when active stones or excess urine calcium are suspected.
- Osteosarcoma occurred in animal studies. Whether Tymlos causes it in humans is unknown; the label advises avoiding use in people with certain elevated baseline risks, including prior skeletal radiation, bone cancer, Paget's disease, or open growth plates.
- Serious allergic reactions have been reported. Signs such as swelling of the face or throat or difficulty breathing require urgent medical attention. The product is contraindicated after severe hypersensitivity to its ingredients.
Product quality
Product identity and quality
Tymlos is a defined prescription product with a specific pen, dose, and storage instructions. Its evidence cannot verify the contents or sterility of products sold under the same ingredient name elsewhere.
Product and prescription
The active ingredient name alone does not establish that a product is Tymlos.
Pen handling
Storage before and after first use differs from some other osteoporosis pens.
Current medication history
Earlier osteoporosis treatment and fracture risk affect the discussion of treatment duration and next steps.
Mechanism
How it is proposed to work
Abaloparatide activates a receptor involved in bone remodeling. Given intermittently, it stimulates bone formation and can increase bone density.
The drug is an analog of PTH-related protein and acts through the PTH1 receptor, which is also relevant to parathyroid hormone signaling.
A change in bone-density measurements is useful evidence, but it is not identical to directly observing fewer fractures in a particular population.
FAQ
Common questions
Is the same fracture outcome established for men?
The label's male indication is to increase bone density. The male placebo-controlled trial measured bone density as its primary endpoint rather than establishing fracture reduction.
Is Tymlos interchangeable with teriparatide?
No. They are different prescription drugs with different labeled doses, storage requirements, and treatment-duration language.
Details
Technical details
Sources
References
- 1.
DailyMed. Tymlos prescribing information
U.S. product label for indications, administration, duration, storage, and safety.
- 2.
doi:10.1001/jama.2016.11136 PMID:27533157 NCT01343004
Randomized placebo comparison with an open-label teriparatide arm in postmenopausal women.
- 3.
Regulatory assessment. Eladynos public assessment report
European assessment of ACTIVE after excluding two sites with serious conduct findings.
- 4.
PubMed. The Efficacy and Safety of Abaloparatide-SC in Men With Osteoporosis: A Randomized Clinical Trial
doi:10.1002/jbmr.4719 PMID:36190391 NCT03512262
Placebo-controlled male osteoporosis trial with lumbar spine bone density as its primary endpoint.
- 5.
doi:10.1210/jc.2018-00163 PMID:29800372 NCT01657162
Extension in which eligible ACTIVE participants received open-label alendronate after abaloparatide or placebo.
- 6.
DailyMed. Forteo prescribing information
U.S. product label for indications, administration, duration, storage, and safety.